288 related articles for article (PubMed ID: 30458987)
1. Exosomal transfer of miR-214 mediates gefitinib resistance in non-small cell lung cancer.
Zhang Y; Li M; Hu C
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):457-464. PubMed ID: 30458987
[TBL] [Abstract][Full Text] [Related]
2. Cancer exosomal microRNAs from gefitinib-resistant lung cancer cells cause therapeutic resistance in gefitinib-sensitive cells.
Azuma Y; Yokobori T; Mogi A; Yajima T; Kosaka T; Iijima M; Shimizu K; Shirabe K; Kuwano H
Surg Today; 2020 Sep; 50(9):1099-1106. PubMed ID: 32052182
[TBL] [Abstract][Full Text] [Related]
3. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway.
Liu X; Jiang T; Li X; Zhao C; Li J; Zhou F; Zhang L; Zhao S; Jia Y; Shi J; Gao G; Li W; Zhao J; Chen X; Su C; Ren S; Zhou C
J Cell Mol Med; 2020 Jan; 24(2):1529-1540. PubMed ID: 31894895
[TBL] [Abstract][Full Text] [Related]
4. Exosomes-transmitted miR-7 reverses gefitinib resistance by targeting YAP in non-small-cell lung cancer.
Chen R; Qian Z; Xu X; Zhang C; Niu Y; Wang Z; Sun J; Zhang X; Yu Y
Pharmacol Res; 2021 Mar; 165():105442. PubMed ID: 33497805
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Qin X; Yu S; Zhou L; Shi M; Hu Y; Xu X; Shen B; Liu S; Yan D; Feng J
Int J Nanomedicine; 2017; 12():3721-3733. PubMed ID: 28553110
[TBL] [Abstract][Full Text] [Related]
6. Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer.
Lei Y; Guo W; Chen B; Chen L; Gong J; Li W
Oncol Rep; 2018 Dec; 40(6):3438-3446. PubMed ID: 30542738
[TBL] [Abstract][Full Text] [Related]
7. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
8. CAFs-Derived Exosomal miRNA-130a Confers Cisplatin Resistance of NSCLC Cells Through PUM2-Dependent Packaging.
Zhang T; Zhang P; Li HX
Int J Nanomedicine; 2021; 16():561-577. PubMed ID: 33542625
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
10. Cancer-associated fibroblasts secreted miR-103a-3p suppresses apoptosis and promotes cisplatin resistance in non-small cell lung cancer.
Wang H; Huang H; Wang L; Liu Y; Wang M; Zhao S; Lu G; Kang X
Aging (Albany NY); 2021 May; 13(10):14456-14468. PubMed ID: 33999859
[TBL] [Abstract][Full Text] [Related]
11. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis.
Song Z; Jia G; Ma P; Cang S
Life Sci; 2021 Jul; 276():119399. PubMed ID: 33781830
[TBL] [Abstract][Full Text] [Related]
12. Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.
Ma Y; Yuwen D; Chen J; Zheng B; Gao J; Fan M; Xue W; Wang Y; Li W; Shu Y; Xu Q; Shen Y
Int J Nanomedicine; 2019; 14():8121-8132. PubMed ID: 31632022
[TBL] [Abstract][Full Text] [Related]
13. miR-365a-5p suppresses gefitinib resistance in non-small-cell lung cancer through targeting PELI3.
Li F; Li H; Li S; Lv B; Shi J; Yan H; Zhang H; He Y
Pharmacogenomics; 2020 Jul; 21(11):771-783. PubMed ID: 32635799
[No Abstract] [Full Text] [Related]
14. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p.
Wu K; Li J; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
Biomed Pharmacother; 2019 Aug; 116():108995. PubMed ID: 31121484
[TBL] [Abstract][Full Text] [Related]
15. Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2/mTOR/P-gp pathway.
Jiang L; Zhang Y; Guo L; Liu C; Wang P; Ren W
BMC Cancer; 2021 Dec; 21(1):1290. PubMed ID: 34856955
[TBL] [Abstract][Full Text] [Related]
16. Prostate carcinoma cell-derived exosomal MicroRNA-26a modulates the metastasis and tumor growth of prostate carcinoma.
Wang X; Wang X; Zhu Z; Li W; Yu G; Jia Z; Wang X
Biomed Pharmacother; 2019 Sep; 117():109109. PubMed ID: 31229922
[TBL] [Abstract][Full Text] [Related]
17. Exosomal Delivery of FTO Confers Gefitinib Resistance to Recipient Cells through ABCC10 Regulation in an m6A-dependent Manner.
Xiao P; Liu YK; Han W; Hu Y; Zhang BY; Liu WL
Mol Cancer Res; 2021 Apr; 19(4):726-738. PubMed ID: 33563765
[TBL] [Abstract][Full Text] [Related]
18. MiR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19.
Wang Y; Lian YM; Ge CY
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5831-5839. PubMed ID: 31298334
[TBL] [Abstract][Full Text] [Related]
19. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract][Full Text] [Related]
20. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]